Drugs / Standard 2016-2017 Flu vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03139565 Comparator | Oct 2016 → Jun 2017 | immunodeficiency disease, influenza | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Standard 2016-2017 Flu vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03139565 ↗ |
| Known as | Fluviral | “We conducted a randomized, double-blind trial to compare the safety and immunogenicity of the 2016-2017 high-dose (HD; FluzoneHD, Sanofi) vs SD (Fluviral, GSK) influenza...” PMID 29253089 ↗ May 2018 |
| Modality | Vaccine | “2016-2017 high-dose (HD; FluzoneHD, Sanofi) vs SD (Fluviral, GSK) influenza vaccine” PMID 29253089 ↗ May 2018 |
| Route | Intramuscular | “The intramuscular preparation of the vaccine used for the control group” NCT03139565 ↗ |